Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Chan

Showing results (71-80 of 271) with videos related to

Pageof 28
Sort By:
Cancer Research Communications|August 2, 2023
Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic VulnerabilitiesIan Ganly, Fengshen Kuo, Vladimir Makarov, et al.
Frontiers in Cardiovascular Medicine|August 26, 2021
Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological MechanismsRishi Rikhi, Jaret Karnuta, Muzna Hussain, et al.
Cell|February 4, 2014
Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedulesKevin Leder, Ken Pitter, Quincey LaPlant, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2013
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the diseaseIñigo Landa, Ian Ganly, Timothy A Chan, et al.
Nature Genetics|September 27, 2016
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapyNadeem Riaz, Jonathan J Havel, Sviatoslav M Kendall, et al.
Oncotarget|February 9, 2017
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomasRobert F Koncar, Zhengtao Chu, Lindsey E Romick-Rosendale, et al.
Journal of Neuro-Oncology|November 6, 2013
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastomaDaniel E Spratt, Michael Folkert, Zachary S Zumsteg, et al.
Oral Oncology|August 19, 2019
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinomaDaniel L Faden, Fei Ding, Yan Lin, et al.
Journal of Neuro-Oncology|October 3, 2014
Ipilimumab and whole brain radiation therapy for melanoma brain metastasesNaamit K Gerber, Robert J Young, Christopher A Barker, et al.
JAMA Oncology|February 18, 2021
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per MegabaseCristina Valero, Mark Lee, Douglas Hoen, et al.
Pageof 28

Showing results (71-80 of 271) with videos related to

Sort By:
Pageof 28
Cancer Research Communications|August 2, 2023
Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic VulnerabilitiesIan Ganly, Fengshen Kuo, Vladimir Makarov, et al.
Frontiers in Cardiovascular Medicine|August 26, 2021
Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological MechanismsRishi Rikhi, Jaret Karnuta, Muzna Hussain, et al.
Cell|February 4, 2014
Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedulesKevin Leder, Ken Pitter, Quincey LaPlant, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2013
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the diseaseIñigo Landa, Ian Ganly, Timothy A Chan, et al.
Nature Genetics|September 27, 2016
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapyNadeem Riaz, Jonathan J Havel, Sviatoslav M Kendall, et al.
Oncotarget|February 9, 2017
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomasRobert F Koncar, Zhengtao Chu, Lindsey E Romick-Rosendale, et al.
Journal of Neuro-Oncology|November 6, 2013
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastomaDaniel E Spratt, Michael Folkert, Zachary S Zumsteg, et al.
Oral Oncology|August 19, 2019
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinomaDaniel L Faden, Fei Ding, Yan Lin, et al.
Journal of Neuro-Oncology|October 3, 2014
Ipilimumab and whole brain radiation therapy for melanoma brain metastasesNaamit K Gerber, Robert J Young, Christopher A Barker, et al.
JAMA Oncology|February 18, 2021
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per MegabaseCristina Valero, Mark Lee, Douglas Hoen, et al.
Pageof 28